Michael Mcalevey Sells 3,892 Shares of HCA Healthcare (NYSE:HCA) Stock

HCA Healthcare, Inc. (NYSE:HCA) EVP Michael Mcalevey sold 3,892 shares of the stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the sale, the executive vice president owned 3,487 shares of the company’s stock, valued at approximately $1,652,105.73. This trade represents a 52.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

HCA Healthcare Trading Down 0.5%

Shares of HCA Healthcare stock opened at $471.00 on Friday. HCA Healthcare, Inc. has a 1-year low of $289.98 and a 1-year high of $478.19. The business has a 50-day moving average price of $426.28 and a two-hundred day moving average price of $390.24. The company has a market cap of $107.48 billion, a P/E ratio of 18.21, a PEG ratio of 1.38 and a beta of 1.41.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, October 24th. The company reported $6.96 EPS for the quarter, topping the consensus estimate of $5.64 by $1.32. The business had revenue of $19.16 billion during the quarter, compared to analysts’ expectations of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The firm’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm posted $4.90 earnings per share. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. Equities research analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, December 15th. HCA Healthcare’s payout ratio is 11.13%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of HCA Healthcare during the 2nd quarter worth approximately $1,152,408,000. Price T Rowe Associates Inc. MD lifted its holdings in HCA Healthcare by 83.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock worth $829,104,000 after acquiring an additional 1,091,416 shares during the period. Viking Global Investors LP grew its stake in HCA Healthcare by 58.5% in the 2nd quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock valued at $717,214,000 after purchasing an additional 690,773 shares during the period. Goldman Sachs Group Inc. increased its holdings in HCA Healthcare by 49.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock worth $615,583,000 after buying an additional 587,036 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of HCA Healthcare during the 1st quarter worth approximately $569,217,000. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on HCA. Jefferies Financial Group raised their target price on HCA Healthcare from $485.00 to $525.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. UBS Group boosted their price objective on HCA Healthcare from $495.00 to $525.00 and gave the company a “buy” rating in a report on Monday, October 27th. The Goldman Sachs Group lifted their price target on shares of HCA Healthcare from $470.00 to $520.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Morgan Stanley set a $425.00 price objective on shares of HCA Healthcare in a research note on Monday, October 27th. Finally, Zacks Research upgraded shares of HCA Healthcare from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, HCA Healthcare presently has an average rating of “Moderate Buy” and an average target price of $473.53.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.